EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)

Fei Ma iD, Binghe Xu, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplasti…

Cancer Innovation · 2026-06 · 5 (3)

DOI: 10.1002/cai2.70062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 29.05.2026. Verfasst von Fei Ma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Scienc…. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer represents a major threat to women's health in China. Its continuously rising incidence contributes to a growing disease burden, thereby creating a critical demand for novel and effective therapeutic strategies. In recent years, poly ADP‐ribose polymerase (PARP) inhibitors, as a novel class of anti‐tumor drugs targeting the DNA damage repair pathway, have demonstrated remarkable efficacy in treating breast cancer with BRCA1/2 mutations. By selectively inhibiting DNA repair in tumor cells, these agents induce a “synthetic lethality” effect, offering a new option for precision therapy. Currently, PARP inhibitors such as Olaparib and Fluzoparib have been approved for clinical use. This consensus, based on the latest evidence‐based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice.

Schlagwörter

Stichwörter der Autor:innen

PARP inhibitorsbreast cancerclinical applicationsafety managementtargeted therapy

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.

ORCID-Profile: Fei Ma

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ma, F., Xu, B., & China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplasti… (2026). Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). Cancer Innovation, 5(3). https://doi.org/10.1002/cai2.70062

Vancouver

Ma F, Xu B, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplasti…. Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). Cancer Innovation. 2026;5(3). doi:10.1002/cai2.70062

BibTeX
@article{Ma2026,
  author = {Ma, Fei and Xu, Binghe and China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplasti…, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplasti…},
  title = {Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition)},
  journal = {Cancer Innovation},
  year = {2026},
  volume = {5},
  number = {3},
  doi = {10.1002/cai2.70062}
}
Kostenlos starten →